Evaluation of Cicaplast in Subjects With Skin Irritation

Status Completed

Clinical Trial Summary

The aim of this open, before/after, multicentric study is to assess the effect and tolerance of Cicaplast Baume B5 in patients having a skin irritation (irritative and cracked dermatitis, dry eczematids, rubbing irritation, ...) under dermatological control. Patients are asked to apply the product at least twice a day until complete recovery (maximum 21 days).

Clinical Trial Description

Dermscan has implemented a quality management system which has been certified by the International Standards Organization (ISO 9001: 2015). This quality assurance system includes appropriate Good Clinical Practices (GCP) and regulation requirements. The proofreader is not involved in the audited study. A certificate of quality inspection signed by the person who checked the report is enclosed in each study. Statistical method Regarding the descriptive analysis, the quantitative data is summarized using the following statistics by time point: - Number of values - Mean - Median - Standard deviation (SD) - Minimum value - Maximum value. Are summarized in frequency (N) and percentage (%) by time point: - the Investigator's Global Assessment (IGA) score assessed by the investigator using a 6-point scale - the soothing effect assessed by the subject using a 4-point scale for the parameters pain and pruritus - each global tolerance score assessed by the investigator and by the subject using a 4-point scale. The score of anti-irritating effect (SCOre de REparation de l'EPIderme= SCOREPI) is summarized using statistics for quantitative variables at each time point. The local signs of irritated area assessed using a 4-point scale (erythema, desquamation, pigmentation, cracks, oedema) are summarized in frequency (N) and percentage (%) and by time point and by parameter. ;

Study Design

Related Conditions & MeSH terms

Skin Diseases

Clinical Trial Details

NCT number	NCT05767333
Study type	Observational
Source	Cosmetique Active International
Contact
Status	Completed
Phase
Start date	October 11, 2021
Completion date	June 6, 2022

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05038982` - Efficacy of Abrocitinib for Reducing Pruritus in Adults With Prurigo Nodularis and Chronic Pruritus of Unknown Origin	Phase 2
Completed	`NCT03563066` - Effect of Benralizumab in Atopic Dermatitis	Phase 2
Recruiting	`NCT04818138` - BROadband vs Narrowband photoTherapy for Eczema Trial Nested in the CACTI Cohort	N/A
Completed	`NCT02916888` - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists	N/A
Completed	`NCT00772447` - China Registration Study in Patients With Skin Infections	Phase 3
Recruiting	`NCT01631617` - Effects of Treatments on Atopic Dermatitis	Phase 2
Active, not recruiting	`NCT04971200` - Pilot Study Assessing the Effect of Tildrakizumab in Vitiligo	Early Phase 1
Completed	`NCT04144491` - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda	N/A
Recruiting	`NCT04138342` - Topical Fluorescent Nanoparticles Conjugated Somatostatin Analog for Suppression and Bioimaging Breast Cancer	Phase 1
Recruiting	`NCT06061471` - To Evaluate the Efficacy and Safety of AK111 Injection in the Treatment of Moderate to Severe Plaque Psoriasis	Phase 2
Terminated	`NCT04775316` - Prospective, International, Multicenter, Observational Study to Evaluate the Clinical Performance and Safety of a Silicone-coated Transparent Postoperative Dressing
Recruiting	`NCT05765461` - Effect of Lipikar Baume AP+M on Quality of Life and Pain of Adults With Dryness or Severe Xerosis
Withdrawn	`NCT04593914` - A Novel Skin Barrier Protectant for Acute Radiodermatitis	N/A
Completed	`NCT03720470` - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy	Phase 3
Recruiting	`NCT06092866` - Digital Versus Telephone Symptom Assessment and Triage in Primary Care	N/A
Recruiting	`NCT04901325` - Baricitinib in the Treatment of Adults With Pyoderma Gangrenosum (PG)	Phase 2
Not yet recruiting	`NCT05102396` - Topical Oxybutynin for Treatment of Hyperidrosis: a Local or a Systemic Effect?	Phase 2
Recruiting	`NCT01917279` - Capecitabine Maintenance Therapy Following Capecitabine Combined With Docetaxel in Treatment of mBC	Phase 3
Completed	`NCT01975038` - Adaption of the Skin Sun Sensitivity Scale	N/A
Recruiting	`NCT01427400` - The Use of Botulinum Toxin A in Two-Stage Tissue Expander/ Implant Breast Reconstruction	Phase 4